News
2009 and Q1 2010 HIGHLIGHTS
In 2010 ClinDatrix began its 8th year in business. ClinDatrix continues to receive a lot of repeat business from very satisfied clients with numerous active projects. By keeping marketing, business development and overhead expenses low, ClinDatrix continues to offer clients high quality service at a reasonable price. Revenue was up 30% in 2009 over 2008.
During 2009 and Q1 2010 ClinDatrix validated the Oracle Clinical database management software, including the Thesaurus Management System and Remote Data Capture. The system was commissioned for production use on March 15, 2010. ClinDatrix is now offering its clients these robust, highly reliable, and scalable applications. These tools will broaden ClinDatrix world class data management and clinical services in the pharmaceutical, biotechnology, and medical device industries.
Implementing the industry’s leading clinical data management system will facilitate ClinDatrix global expansion into Phase III clinical trials. The company is launching two Phase III trials using Electronic Data Capture (EDC) in Q1 2010, for different sponsors. Customized self-paced online training for investigational sites is being provided along with 24/7 technical support. The Oracle suite will provide site personnel with a simplified EDC user interface. Discrepancy management is eased by providing immediate validation checks, batched validation checks, and remote monitoring. Oracle Thesaurus Management System facilitates coding of medical terminology and supports all dictionaries required by international regulatory authorities.
”Oracle Clinical and Oracle Remote Data Capture provide an integrated EDC solution that uses the same database for either paper or EDC data submissions. This is a strong feature from a Data Management perspective” says Louise M. Murphy, PhD, MBA, ClinDatrix President and CEO.
ClinDatrix was founded in 2003 by Drs. Brian and Louise Murphy to provide a personalized approach to the critical aspects of clinical research, data management, and statistics in the biotechnology, medical device, and pharmaceutical industries. The company is 97.5% employee-owned.